Behavioral Health Reforms And Demographic Trends Will Expand Healthcare Facilities

The analyst price target for Acadia Healthcare has been reduced by approximately $0.71 to $29.71. Analysts cited weaker revenue growth, modestly lower profit margin expectations, and continued operational challenges as reflected in recent research updates.

Analysts have lowered Acadia Healthcare’s price target to $30.43 amid execution missteps, persistent growth and free cash flow delays, and reduced FY25 guidance, with only limited benefit from recent one-time TN DPP gains. Analyst Commentary Bearish analysts cite continued execution missteps, including missed Q2 consensus estimates and uncertainty surrounding the impact of Medicaid Redeterminations and the One Big Beautiful Bill Act.

Acadia Healthcare Company's fair value has been revised downward, primarily driven by a notable decline in its projected future P/E and an increased discount rate, resulting in a lower consensus price target from $41.86 to $38.21. What's in the News Acadia Healthcare completed a buyback of 1,706,807 shares (1.84% of shares outstanding) for $50.02 million as of June 30, 2025.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has decreased future PE multiple from 19.6x to 17.1x.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

AnalystConsensusTarget has decreased revenue growth from 9.0% to 7.4%, decreased profit margin from 9.7% to 7.2% and increased future PE multiple from 17.7x to 19.9x.